Outsourcing Pharma
MARCH 16, 2022
An expert from the R&D tech provider discusses how automation, integration, and other tools can help with effective access and analysis of lab information.
Pharma Tutor
MARCH 16, 2022
ARTICLE ON FUTURISTIC APPROACH FOR MEDICAL DIAGNOSTICS ; BIOCHIP. About Author. Meenu Maurya. Email : meenudinesh15@gmail.com. admin. Wed, 03/16/2022 - 15:06. Tags. Articles.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
MARCH 16, 2022
While strides have been made recruiting more representative patient populations, more can and should be done, according to an Oracle Health Sciences leader.
Roots Analysis
MARCH 16, 2022
Over the years, applications of exosomes in therapeutics have undergone an evolutionary change, in terms of cost of research, technology used, and duration of the study. Moreover, various startups and small firms have entered into collaborations in order to advance their innovations and offer specialized research expertise, services and technologies.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Outsourcing Pharma
MARCH 16, 2022
A leader from the patient recruitment specialist discusses the industryâs ongoing challenges with patient population diversity, and potential solutions.
pharmaphorum
MARCH 16, 2022
Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca’s top-selling respiratory drug Symbicort, although launch plans remain uncertain for now. Viatris’ generic of Symbicort (budesonide and formoterol fumarate dihydrate) – developed by Viatris in collaboration with 3M spin-off company Kindeva Drug Delivery and called Breyna – has been cleared for the same indications as the brand, namely maintenance treatment for asthma
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
pharmaphorum
MARCH 16, 2022
Merck & Co’s two powerhouse oncology drugs – Keytruda and Lynparza – have failed to show efficacy when used in combination for patients with previously treated metastatic castration-resistant prostate cancer (mCRPC). The disappointing result comes from the KEYLYNK-010 trial, which looked at the combination of PD-1 inhibitor Keytruda (pembrolizumab) with AstraZeneca-partnered PARP inhibitor Lynparza (olaparib) in men whose cancer had progressed after chemotherapy and anti-androgen thera
Board Vitals - Pharmacist
MARCH 16, 2022
There’s no way around it, medical school is expensive and unfortunately for medical students, the costs have been increasing over the past several years. According to the Association of American Medical Colleges , the average cost of medical school including tuition, fees, and health insurance for first-year students attending in-state public schools in 2021-2022 was $39,237, a 29% increase from the cost in 2012-13 ($30,192).
NF2 BioSolutions
MARCH 16, 2022
Hi I’m Amy. My NF journey begun at 10, well that’s when we found the first tumour. Doctors can’t be sure if I lived with it my whole life, since, unlike many people with NF, the genetic defect does not run in my family. Lucky me eh!? I am very fortunate that here in the U.K., I am treated by an entire team of NF specialists from Consultants to Nurses to Psychologists I have access to a tonne of support.
pharmaphorum
MARCH 16, 2022
Apellis chances of getting regulatory approval for pegcetacoplan, its drug candidate for sight-robbing disease geographic atrophy (GA), may have been heightened by new follow-up data from two phase 3 trials. Before today’s readout, the score was one win and one loss for pegcetacoplan in the OAKS and DERBY trials respectively after 12 months’ treatment with the drug.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Outsourcing Pharma
MARCH 16, 2022
A leader from the trial platform company discusses how patient experience can be enhanced when the clinical trial team shares a background with the subjects.
Pharmacy Friday Pearls
MARCH 16, 2022
Download PDF. Introduction . 1. Commonly identified as symptoms, including nausea, cyclic vomiting and abdominal pain, that are refractory to available antiemetics and analgesics. 2. Patients tend to take compulsive hot baths/showers for symptom relief. 3. Characteristically distinguished from cyclic vomiting syndrome, these symptoms are usually preceded by years of chronic cannabis use and symptoms are typically resolved with cessation of cannabis use. 4.
Med Ed 101
MARCH 16, 2022
I’ve been doing quite a bit of long term care consulting lately and I’ve been trying to pay attention to which medications and medication classes I have been targeting in an effort to reduce polypharmacy. Here are my top 5 targets to reduce medications in long term care. Also be sure to check out my […]. The post Top 5 Targets To Reduce Medications In Long Term Care appeared first on Med Ed 101.
Pharma Times
MARCH 16, 2022
Patients who were bedridden for seven days or longer were at increased risk of depression and anxiety over the study period
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
MARCH 16, 2022
How to make it in the new normal. Part 1 of this article discussed the massive disruptions to medical events caused by the COVID-19 pandemic and how attendees’ preferences have shifted as things have shaken out. You can read part 1 here. In part 2, we look at how some affected groups can respond. Pharmas confront a steep learning curve. For the pharmaceutical industry, the disruption of the medical conference landscape came as a shock since its focus had traditionally been on participation
Pharma Times
MARCH 16, 2022
Better treatment for conditions experienced by individuals who were exposed to alcohol before birth
pharmaphorum
MARCH 16, 2022
Precirix has raised €80 million ($88 million) in a second-round financing that will be used to advance multiple radiopharmaceutical candidates for cancer through clinical development. The Belgian biotech, which was spun out from the Vrije Universiteit Brussel in 2014, is developing a pipeline of radio-labelled, single-chain antibodies led by CAM-H2, currently in a phase 1/2 study in patients with HER2-positive metastatic breast and gastric cancers.
pharmaphorum
MARCH 16, 2022
Earlier this week, Pfizer chief executive Albert Bourla said that a second booster of its COVID-19 vaccine will be necessary to keep the pandemic under control, and the company has now asked the FDA to back this use. The company and partner BioNTech have filed for emergency use authorisation of a fourth dose of Comirnaty based on real-world safety and efficacy data from Israel, where a fourth dose has been authorised for people aged 60 and over and those in high-risk groups.
Expert insights. Personalized for you.
98 
Let's personalize your content